# Biomarin (BMRN) — News

BMRN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bmrn/news

## Recent headlines

- [Alzheimer stocks rose in after-hours trading, with Anavex Life Sciences up 2.9%, while Alnylam Pharmaceuticals and BioMarin Pharmaceutical gained.](https://www.ainvest.com/news/alzheimer-stocks-rose-hours-trading-anavex-life-sciences-2-9-alnylam-pharmaceuticals-biomarin-pharmaceutical-gained-2610-45) — AInvest Wire, Oct 15, 2026
  Alzheimer's disease-related stocks saw gains in after-hours trading on October 15, 2026. Anavex Life Sciences (Nasdaq: AVXL) rose 2.9%, reflecting investor optimism about its pipeline of therapies targeting neurodegenerative conditions. Alnylam Pharmaceuticals (Nasdaq: ALNY) and BioMarin…
- [Biomarin Pharmaceutical: Barclays raises target price to $114 from $111](https://www.ainvest.com/news/biomarin-pharmaceutical-barclays-raises-target-price-114-111-2610) — AInvest Wire, Oct 14, 2026
- [JSE: BYI - Results for the six months ended 31 August 2026 and declaration of cash dividend](https://www.ainvest.com/news/jse-byi-results-months-ended-31-august-2026-declaration-cash-dividend-2610) — AInvest Wire, Oct 13, 2026
- [Omron aims to build physical AI platform that uses AI running on industrial computers to operate machinery & robots in coordination - Nikkei](https://www.ainvest.com/news/omron-aims-build-physical-ai-platform-ai-running-industrial-computers-operate-machinery-robots-coordination-nikkei-2610) — AInvest Wire, Oct 12, 2026
  Omron, a Japanese automation and industrial equipment manufacturer, is developing a physical AI platform designed to integrate artificial intelligence with industrial computing systems to coordinate the operation of machinery and robots. According to a report by Nikkei , the initiative aims to…
- [Biomarin Pharmaceutical Inc.: Raymond James raises to strong buy from outperform](https://www.ainvest.com/news/biomarin-pharmaceutical-raymond-james-raises-strong-buy-outperform-2610) — AInvest Wire, Oct 12, 2026
  Raymond James has upgraded its rating for BioMarin Pharmaceutical Inc. (BMRN) to "strong buy" from "outperform," reflecting growing confidence in the company’s strategic direction and financial performance. The move aligns with recent analyst activity, as 24 analysts currently cover the stock, with…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).